IO Biotech - IOBT Competitors

IO Biotech (NASDAQ:IOBT) and Abeona Therapeutics (NASDAQ:ABEO) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their risk, analyst recommendations, valuation, media sentiment, institutional ownership, earnings, profitability, dividends and community ranking.

Which has more volatility & risk, IOBT or ABEO?

IO Biotech has a beta of -0.61, indicating that its share price is 161% less volatile than the S&P 500. Comparatively, Abeona Therapeutics has a beta of 1.2, indicating that its share price is 20% more volatile than the S&P 500.

Does the media prefer IOBT or ABEO?

In the previous week, IO Biotech had 11 more articles in the media than Abeona Therapeutics. MarketBeat recorded 17 mentions for IO Biotech and 6 mentions for Abeona Therapeutics. IO Biotech's average media sentiment score of 0.73 beat Abeona Therapeutics' score of 0.14 indicating that IO Biotech is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
IO Biotech	0 Very Positive mention(s)	3 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Abeona Therapeutics	1 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Do insiders & institutionals believe in IOBT or ABEO?

53.2% of IO Biotech shares are held by institutional investors. Comparatively, 37.7% of Abeona Therapeutics shares are held by institutional investors. 11.6% of IO Biotech shares are held by insiders. Comparatively, 2.4% of Abeona Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Is IOBT or ABEO more profitable?

IO Biotech's return on equity of -43.58% beat Abeona Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
IO Biotech	N/A	-43.58%	-41.05%
Abeona Therapeutics	N/A	-157.61%	-85.45%

Does the MarketBeat Community favor IOBT or ABEO?

Abeona Therapeutics received 503 more outperform votes than IO Biotech when rated by MarketBeat users. However, 88.89% of users gave IO Biotech an outperform vote while only 71.27% of users gave Abeona Therapeutics an outperform vote.

Company	Underperform	Outperform
IO Biotech	Outperform Votes 8 88.89%	Underperform Votes 1 11.11%
Abeona Therapeutics	Outperform Votes 511 71.27%	Underperform Votes 206 28.73%

Do analysts rate IOBT or ABEO?

IO Biotech currently has a consensus target price of $10.50, suggesting a potential upside of 412.20%. Abeona Therapeutics has a consensus target price of $40.00, suggesting a potential upside of 1,566.67%. Given Abeona Therapeutics' higher probable upside, analysts clearly believe Abeona Therapeutics is more favorable than IO Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
IO Biotech	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00
Abeona Therapeutics	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00

Which has better earnings & valuation, IOBT or ABEO?

IO Biotech has higher earnings, but lower revenue than Abeona Therapeutics. IO Biotech is trading at a lower price-to-earnings ratio than Abeona Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
IO Biotech	N/A	N/A	-$71.46 million	-$2.49	-0.82
Abeona Therapeutics	$3 million	13.74	-$84.94 million	-$18.31	-0.13

Summary

IO Biotech beats Abeona Therapeutics on 9 of the 14 factors compared between the two stocks.